CDK1 and hepatocellular carcinoma: Consistent with this finding, blocking CDK1 with RO-3306 increased the efficacy of sorafenib and cisplatin treatment in preclinical models of hepatocellular carcinoma and epithelial ovarian cancer, respectively41,42.